Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Ozurdex
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:dosage_form |
implant
|
| gptkbp:effective_date |
gptkb:2014
|
| gptkbp:formulation |
sustained-release implant
|
| https://www.w3.org/2000/01/rdf-schema#label |
Iluvien
|
| gptkbp:ingredients |
fluocinolone acetonide
|
| gptkbp:is_used_for |
treatment of diabetic macular edema
|
| gptkbp:manager |
intravitreal injection
|
| gptkbp:manufacturer |
Alimera Sciences
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:United_States |
| gptkbp:side_effect |
retinal detachment
eye pain intraocular pressure increase vision changes cataract formation |